Volume 12, Issue 3 (May & June 2021)
BCN 2021, 12(3): 309-314 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mirzaii-Dizgah M H, Mirzaii-Dizgah M R, Mirzaii-Dizgah I. Serum and Saliva Myelin Basic Protein as Multiple Sclerosis Biomarker. BCN 2021; 12 (3) :309-314
URL: http://bcn.iums.ac.ir/article-1-1573-en.html
URL: http://bcn.iums.ac.ir/article-1-1573-en.html
1- Student Research Committee, School of Dentistry, AJA University of Medical Sciences, Tehran, Iran.
2- Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
3- Department of Physiology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.
2- Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
3- Department of Physiology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.
Abstract:
Introduction: Multiple Sclerosis (MS) is presented with motor and sensory function loss. It is caused by demyelination and following axonal lesion. As Myelin Basic Protein (MBP) is one of the key elements of the myelin cover, we examined the level of MBP in serum, stimulated, and unstimulated saliva as a suitable biomarker for detecting MS.
Methods: A case-control study was performed in 29 healthy women and 32 definitive relapsing-remitting MS patients hospitalized in Imam Reza hospital, Tehran, Iran. MBP level was assayed in serum and stimulated and unstimulated whole saliva.
Results: MBP was expressed at a lower level in serum and stimulated saliva of MS patients compared to the control group. The serum MBP level had a considerable correlation with its stimulated saliva level. The receiver operating characteristic analysis showed significant diagnostic ability for MBP to discriminate MS patients with serum and stimulated saliva from controls.
Conclusion: Serum and saliva level of MBP is lower in MS, so it may be considered a potential biomarker in MS.
Methods: A case-control study was performed in 29 healthy women and 32 definitive relapsing-remitting MS patients hospitalized in Imam Reza hospital, Tehran, Iran. MBP level was assayed in serum and stimulated and unstimulated whole saliva.
Results: MBP was expressed at a lower level in serum and stimulated saliva of MS patients compared to the control group. The serum MBP level had a considerable correlation with its stimulated saliva level. The receiver operating characteristic analysis showed significant diagnostic ability for MBP to discriminate MS patients with serum and stimulated saliva from controls.
Conclusion: Serum and saliva level of MBP is lower in MS, so it may be considered a potential biomarker in MS.
Type of Study: Original |
Subject:
Clinical Neuroscience
Received: 2019/08/3 | Accepted: 2020/11/23 | Published: 2021/05/1
Received: 2019/08/3 | Accepted: 2020/11/23 | Published: 2021/05/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
All the work in this journal are licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
Contact Information
Publisher Tel:
+9821 453 55 555; +9821 453 55 000 (EXT: 104)
Publisher Email: info
nirp.ir
